Management of Increased Storage Iron (3+) with Confirmed Iron Overload
Diagnostic Workup
- The American Journal of Hematology recommends obtaining serum ferritin level and transferrin saturation (TSAT) measurements to guide treatment decisions, with TSAT essential to differentiate true iron overload from inflammatory states 1, 2
- HFE genetic testing is recommended to screen for C282Y and H63D mutations to diagnose hereditary hemochromatosis, the most common primary cause 2
Treatment Algorithm
- The American Journal of Hematology suggests that therapeutic phlebotomy is first-line treatment for primary iron overload (hereditary hemochromatosis) once diagnosis is confirmed, with a target ferritin <50 μg/L during depletion phase 1, 2
- For transfusion-dependent iron overload, iron chelation therapy is the treatment of choice, with deferasirox as the primary oral chelating agent, and a starting dose of 14-20 mg/kg/day 1, 2
Chelation Regimens
- The American Journal of Hematology recommends continuing chelation as long as the patient requires transfusions and iron overload remains clinically relevant, with monitoring of ferritin at minimum every 3 months 1, 4, 5
- The target ferritin decline is <1,000 ng/mL during treatment, and chelation should be withheld when ferritin declines to <1,000 ng/mL and no additional transfusions are needed 5, 4, 2
Special Populations
- The American Journal of Hematology suggests initiating chelation pre-transplant if ferritin >1,000 ng/mL to decrease hepatic complications and mortality in patients undergoing allogeneic stem cell transplant 1, 8
- For idiopathic myelofibrosis, chelation should be considered in patients with favorable/intermediate prognostic score who are transfusion-dependent and meet iron overload criteria 1, 4
Organ-Specific Monitoring
- The American Journal of Hematology recommends assessing for target organ damage, including liver function tests, ultrasound or FibroScan for cirrhosis assessment, cardiac echocardiogram if symptoms or significantly elevated ferritin, endocrine screening for diabetes and hypogonadism, and joint assessment for arthropathy 2, 3